Advancing The Future Of Medicine By Getting Back To Its Genetic Roots [Forbes]
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: Forbes
The human genome is driving healthcare innovation, and the biopharmaceutical industry is increasingly focusing research and development centered on understanding the role of genetics in health and disease. The explosion in our understanding of human genetics and disease biology—combined with advanced technology—may hold the key to addressing some of the most intractable diseases at their very source. The Path from Proteins to Genes At , we have spent over three decades honing a deep expertise in disease biology and genetics. By rigorously pursuing an understanding of pathobiology—the mechanisms by which diseases happen—our portfolio of antibody medicines has treated countless patients with difficult-to-treat diseases. This same drive to gain a true understanding of disease origins has naturally led us to advance our expertise into genetic medicines. “An antibody works by binding to something on the surface of a cell or something that is circulating in the human body,” says Ch
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- Intellia Therapeutics, Inc. (NTLA) Just Overtook the 50-Day Moving Average [Yahoo! Finance]Yahoo! Finance
- Earnings Beat: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics, Inc. (NASDAQ: NTLA) was upgraded by analysts at StockNews.com to a "sell" rating.MarketBeat
- Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Citigroup Inc. from $31.00 to $29.00. They now have a "neutral" rating on the stock.MarketBeat
- Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
NTLA
Earnings
- 5/9/24 - Beat
NTLA
Sec Filings
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 4/29/24 - Form ARS
- NTLA's page on the SEC website